Clinical trials: High-Risk Neuroblastoma, open to volunteers
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk…
- Trial name
- HR-NBL2 (NCT04221035)
- Testing
- Vincristine, Carboplatin, Etoposide
- Where
- 142 sites in Australia, Austria and 18 more
- Volunteers
- 800 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Neuroblastoma (NB), Ganglioneuroblastoma
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the…
- Trial name
- NB-NK-2026 (NCT07375563)
- Testing
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell product
- Where
- Russia
- Volunteers
- 5 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Neuroblastoma
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
The goal of this clinical trial is to to assess the dose level of dinutuximab Beta (DB) when combined with 2 different induction chemotherapy regimens (named GPOH or rapid COJEC) in newly diagnosed high-risk neuroblastoma…
- Trial name
- DBPilot (NCT06485947)
- Testing
- Dinutuximab beta, chemotherapy treatment called GPOH, chemotherapy treatment called rapid COJEC
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi
High Risk Neuroblastoma
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma
This clinical trial investigates the safety, side effects, and effectiveness of combining an immunotherapy drug called dinutuximab-beta with standard induction chemotherapy for patients newly diagnosed with high-risk…
- Trial name
- NCT07688252
- Testing
- Dinutuximab Beta, Induction chemotherapy
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
High-Risk Neuroblastoma
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years.
- Trial name
- SHINE (NCT07549321)
- Testing
- hu1418K322A + Temozolomide + Irinotecan
- Where
- 19 sites in United States, Canada and 5 more
- Volunteers
- 144 people
- Sponsor
- Renaissance Pharma Ltd.
Melanoma, Medullary Thyroid Cancer
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.
- Conditions
- Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma
- Trial name
- RABBIT (NCT06814496)
- Testing
- Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Neuroblastoma, High-risk Neuroblastoma
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
- Conditions
- Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
- Trial name
- NCT06057948
- Testing
- OPT-821 (QS-21), oral β-glucan
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for…
- Trial name
- NCT04936529
- Testing
- β-glucan, GM-CSF, OPT-821
- Where
- United States
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and…
- Trial name
- NCT06013618
- Testing
- Naxitamab monotherapy, GM-CSF, Irinotecan
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen University Cancer Center
High-Risk Neuroblastoma
Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease
Safety evaluation and initial efficacy evaluation will be conducted in a group of patients as a non-commercial, open-label clinical trial of dinutuximab beta (Qarziba) phase IIa.
- Trial name
- ChIm-NB-PL (NCT05272371)
- Testing
- Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Jagiellonian University
Dementia, Movement Disorders
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
The goal of this clinical study is to compare the current standard-of-care PET/CT scanner with the new NeuroEXPLORER PET/CT, with the aim of demonstrating the added diagnostic value of the new scanner.
- Conditions
- Dementia, Movement Disorders, ALS - Amyotrophic Lateral Sclerosis, Epilepsy
- Trial name
- NCT07595666
- Testing
- Standard-of-care PET/CT, NeuroEXPLORER
- Where
- Belgium
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Neuroblastoma
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
Neuroblastoma is the most common extracranial solid tumor, with more than half of the patients diagnosed at the metastatic stage, classified as high-risk. High-risk neuroblastoma has a poor prognosis and low survival rate.
- Trial name
- NCT06631391
- Testing
- umbilical cord blood NK cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Neuroblastoma, Sarcoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon…
- Trial name
- NCT05135975
- Testing
- Cabozantinib
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Nationwide Children's Hospital
Neuroblastoma
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard…
- Trial name
- PEDS-PLAN (NCT02559778)
- Testing
- Ceritinib, dasatinib, sorafenib
- Where
- 28 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Giselle Sholler